T
Tahoe Therapeutics
AI-powered in vivo drug discovery platform.
About Tahoe Therapeutics
Tahoe Therapeutics is a biotechnology company engineering AI-powered models of human cells to facilitate the design of improved drugs for a wider range of patients. The company was established in 2022 as Vevo Therapeutics and rebranded to Tahoe Therapeutics in April 2025. It was co-founded by CEO Nima Alidoust, CSO Johnny Yu, Hani Goodarzi, and Kevan Shokat. The founding team combines deep expertise in single-cell genomics, machine learning, and drug discovery. The company's scientific basis originates from Yu's doctoral research at the University of California San Francisco (UCSF), where he, Goodarzi, and Shokat developed the core technology. Tahoe addresses a primary challenge in drug discovery: the high failure rate of drugs developed using traditional in vitro models, which often do not accurately represent complex diseases in humans. The company's core technology is the Mosaic™ platform, which enables in vivo data generation at a massive scale and with single-cell precision. This platform allows for the pooling of cells from hundreds of diverse patient models into a single experiment, such as a mosaic tumor implanted in a mouse, to measure how different cells react to thousands of compounds. This method captures the heterogeneity of disease and drug response across different patients and organs, a significant advancement over standard preclinical research. Using Mosaic, Tahoe is building the world's largest in vivo atlas of how drugs interact with patient cells. A key achievement is the creation of Tahoe-100M, a gigascale single-cell dataset with 100 million data points mapping 60,000 drug-cell interactions. This dataset, 50 times larger than previously available public perturbation data, is used to train the company's AI models to uncover novel drug targets and candidates, particularly for hard-to-treat cancers. The company's initial focus is on oncology, specifically targets within the RAS network. Tahoe's business model involves leveraging its platform for internal drug development and strategic partnerships. The company is advancing its own therapeutic programs towards clinical trials and plans to collaborate with a major pharmaceutical or AI company to share its next, larger dataset to accelerate the development of new medicines or AI models. In January 2026, Tahoe formed a joint venture with Alloy Therapeutics to develop antibody-drug conjugates for difficult cancers. Headquartered in South San Francisco, California, Tahoe has secured $42 million in total funding, with a valuation of $120 million as of August 2025. Its investors include Amplify Partners, General Catalyst, Wing Venture Capital, and Databricks Ventures.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 35
- Open positions
- 1
- Dealroom signal
- 91.3/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotechnology, Oncology, Drug Development, Core AI, AI Drug Discovery, CompBio
- Technology
- Artificial Intelligence, Big Data, Deep Tech
- Business model
- SaaS
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Aug 2025 | $30M | $120M | Overlap Holdings · Conviction · Databricks Ventures · General Catalyst | ↗ |
| SEED✓Equity / VC | Dec 2022 | $12M | $48M | Camford Capital · AIX Ventures · Wing Venture Capital · Mubadala Capital | ↗ |
Growth signals
Latest recorded traffic for Tahoe Therapeutics is 5.7K monthly website visits, down 18.6% over the last three months. Tahoe Therapeutics's team grew 12.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tahoe Therapeutics in the South San Francisco ecosystem
The Tahoe Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Wing Venture Capital
General Catalyst
Camford Capital
AIX Ventures
Mubadala Capital
Series A5 investors entered at this stage
Amplify Partners
Overlap Holdings
Conviction
Databricks Ventures
Civilization Ventures
Other known investors2 additional known investors
Ayman Alabdallah
Shaun Johnson
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tahoe Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tahoe Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









